Cedar Pollen Allergy Pipeline Therapeutics Development Review H2 2015

Press Release   •   Jan 25, 2016 08:48 EST

This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Cedar Pollen Allergy” addition with 20 market data tables and 10 figures, spread across 45 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Anergis SA, Biomay AG, Circassia Pharmaceuticals Plc, Immunomic Therapeutics, Inc., Japan Tobacco Inc. and REGiMMUNE Corporation

Drugs Profile Discussed in this Research:

AllerJ, ASP-4070, Drugs for Cedar Pollen Allergy, japanese cedar hypoallergenic vaccine, JCC-LAMP-Vax, MC-LAMP-Vax, RGI-1001, TO-206, Vaccine for Cedar Pollen Allergy and Vaccine for Japanese Cedar Pollen Allergy

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Allergy therapeutics Market.

Allergies are caused when the immune system us not strong and gets prone pollen or dust. The substances that cause allergy are called allergens like lot of Histamine in the cells causes allergy causing sneezing, itching in the eyes, wheezing etc. It is very necessary to keep our surrounding clean and free from dust. To maintain a clean atmosphere one must clean their house floors regularly and even bed spreads to avoid allergies due to dust mines. Allergies occur even due to pets around the house and one must keep their pets clean by cleaning them well at least once a week. One must not sleep with pets in their bedroom.

Allergy therapeutics is a pharmaceutical company which provides medicines for different allergies which are caused due to stings, foods and due to medicinal reaction. They help to prevent the allergy and common among them being the hay fever or house dust mite allergy. Now day's allergy vaccines are also available and are effective in treating the allergy due to insects like bees and wasp. We must take care of their health as our body's immune system is the one which helps us to fight against these allergies. This can be achieved by keeping the surrounding free of pollution as these allergies would cause great discomfort to an individual. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries